the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)

NCT05527704 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

608

Enrollment

OTHER

Sponsor class

Conditions

TTN
Respiratory Failure
PPHN

Interventions

DRUG: Salbutamol
DRUG: 0,9% Chloride Sodium

Sponsor

Medical University of Warsaw

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]